Share:
CytoDyn filed with FDA for expanded access use of leronlimab for multi-drug resistant HIV patients, and submitted protocol with FDA for Phase 3 registrational trial of leronlimab for critically ill COVID-19 population:
- CytoDyn files for expanded access use of leronlimab for multi-drug resistance HIV patients
- CytoDyn submits protocol with the FDA for Phase 3 registrational trial of leronlimab for critically ill COVID-19 population
Related HIV and Co-Infections News
-
TheBodyPro: Broadly neutralizing antibodies are back in the conversation about how HIV treatment will evolve
-
Infectious Disease Advisor: Breakthrough COVID-19 does not meaningfully affect HIV CD4+ count
-
[Press release] Gilead and Merck announce positive topline results from two Phase 3 studies evaluating islatravir/lenacapavir, an oral once-weekly HIV treatment
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.